Fig. 5: ASRGL1 silencing impairs protein degradation.
From: TDP-43 proteinopathy in ALS is triggered by loss of ASRGL1 and associated with HML-2 expression
a, b Neuronal cultures were transfected with ASRGL1 shRNAs or scrambled shRNAs. a Representative image of a western blot for ubiquitinated proteins. b Comparison of ubiquitinated proteins levels in percentage relative to the scrambled shRNA transfected cells (Brown-Forsythe ANOVA test with Bonferroni correction; Mean ± SEM; number of experimental replicates = 3)). c, d After transfection with scrambled shRNAs or ASRGL1 shRNAs, neuronal cultures were treated with cycloheximide (CHX) for 6 h. c Representative blot showing the levels of TDP-43 before and after 6 h of CHX. d Percentage of variation in TDP-43 levels after 6 h of CHX (number of experimental replicates = 3; Unpaired T-test; Mean ± SEM). e, f Neuronal cultures were transfected with ASRGL1 shRNAs or scrambled shRNAs. e Western blot of spliced XBP1 (sXBP1), unspliced (uXBP1) and vinculin in ASRGL1-silenced and control neurons. f Comparison of sXBP1 levels in percentage relative to the scrambled shRNA transfected cells (Mann–Whitney test; Median (IQR); number of experimental replicates = 4). All pairwise comparisons in the Figure were performed with two-sided tests. Source data are provided as a Source Data file.
